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Cholestasis is an impairment of bile formation/ﬂow at the level of
the hepatocyte and/or cholangiocyte. The ﬁrst, and for the
moment, most established medical treatment is the natural bile
acid (BA) ursodeoxycholic acid (UDCA). This secretagogue
improves, e.g. in intrahepatic cholestasis of pregnancy or early
stage primary biliary cirrhosis, impaired hepatocellular and
cholangiocellular bile formation mainly by complex post-tran-
scriptional mechanisms. The limited efﬁcacy of UDCA in various
cholestatic conditions urges for development of novel therapeutic
approaches. These include nuclear and membrane receptor
agonists and BA derivatives. The nuclear receptors farnesoid X
receptor (FXR), retinoid X receptor (RXR), peroxisome prolif-
erator-activated receptor a (PPARa), and pregnane X receptor
(PXR) are transcriptional modiﬁers of bile formation and at pre-
sent are under investigation as promising targets for therapeutic
interventions in cholestatic disorders. The membrane receptors
ﬁbroblast growth factor receptor 4 (FGFR4) and apical sodium
BA transporter (ASBT) deserve attention as additional therapeutic
targets, as does the potential therapeutic agent norUDCA, a 23-C
homologue of UDCA. Here, we provide an overview on estab-
lished and future promising therapeutic agents and theirJournal of Hepatology 20
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Bile was ﬁrst mentioned in the Ebers Papyrus (circa 1550 B.C.) as
a useful remedy and purge [1]. Dried black bear’s bile rich in
ursodeoxycholic acid (UDCA) was recommended in China for
treatment of jaundice at times of the Tang dynasty (618-907
A.D.) as documented in the Tang Materia Medica, the ﬁrst state
pharmacopoeia worldwide. In the Western hemisphere, bile
had been regarded as a major constituent of the human body
by the Corpus Hippocraticum and Galen of Pergamon, but was
increasingly seen as a useless excrement by the 16th and 17th
century (‘‘cloaca sordium et superﬂuitatum’’) [1]. Only during
the last centuries, the digestive function of bile was recognized
and during the last 30 years the signaling and therapeutic poten-
tial of its major constituents, bile acids (BAs), and the (patho-)
physiological role of BAs, phospholipids, bicarbonate and other
bile constituents were unraveled. Today, bile formation is regard-
ed as a vital secretory process modulated by complex transcrip-
tional and post-transcriptional mechanisms in hepatocytes,
cholangiocytes and ileocytes [2–4].
Cholestasis is an impairment of bile formation and ﬂow. It
may result from; (i) hepatocellular and/or cholangiocellular
secretory defects; or (ii) obstruction of bile ducts by bile duct
lesions, stones or tumours, but may also be related to mixed
mechanisms in conditions such as primary biliary cirrho-
sis/cholangitis (PBC) or primary sclerosing cholangitis (PSC). For
adequate treatment of cholestasis and cholestatic injury, identiﬁ-
cation and targeting of the defective hepatocellular and cholan-
giocellular secretory mechanisms and/or bile duct lesions (or
removal of obstructing stones and tumours) is required.
Evolving pathophysiological insights in cholestatic disorders, par-
ticularly chronic ﬁbrosing cholangiopathies such as PBC, PSC and
(other) secondary forms of cholangitis, provide novel opportuni-
ties for the development of therapeutic approaches for these
disorders. Currently, treatment with UDCA may slow the15 vol. 62 j S25–S37
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progression of chronic cholangiopathies, but has limited or no
proven efﬁcacy in various chronic cholestatic disorders and can-
not heal them. Immunosuppressive/immunomodulating inter-
ventions aiming to minimize immune-mediated damage in
immune-mediated/autoimmune cholestatic disorders such as
PBC and PSC have disappointed in the past, but new approaches,
which are beyond the scope of this review, are at present under
consideration for clinical evaluation. The use of speciﬁc modiﬁers
of hepatobiliary secretory and cellular protection mechanisms
against BA-mediated cytotoxicity may eventually give rise to
new classes of disease-modifying drugs. Here, we provide an
overview of transcriptional and post-transcriptional modulators
of bile formation which may serve as therapeutic agents in the
future for the treatment of cholestatic disorders.UDCA: clinical use
Therapy with natural BAs arose in the 1970s when it was discov-
ered that oral administration of chenodeoxycholic acid (CDCA)
induces the dissolution of cholesterol gallstones. However,
CDCA induced biliary cirrhosis in some species and was shown
to be mildly hepatotoxic and induced dose-dependent diarrhea
in humans [5]. Thereafter, UDCA was shown to have similar efﬁ-
cacy in gallstone disease without any side effects [6]. The
markedly different behaviour of the two natural BAs was ascer-
tained by numerous experimental studies in vitro and in vivo.
UDCA was thereafter proposed as a potential therapeutic
approach for chronic cholestatic disorders with the following
rationale: (a) accumulation of toxic BAs might be at least in part
responsible for liver injury in chronic cholestasis; (b) replace-
ment of endogenous BAs by a non-toxic BA (UDCA) could protect
the liver and slow down the progression of these disorders. This
hypothesis was ﬁrst tested in PBC [7]. UDCA was shown to pro-
vide marked improvement in serum liver tests [7,8]. Placebo-con-
trolled trials showed that UDCA also improves histological
features and delays progression to cirrhosis and the time to liver
transplantation [9–14]. Today, UDCA therapy is recommended for
all patients with PBC provided that they show abnormal serum
liver tests [15,16]. The accepted optimal dose is 13–15 mg/
kg/day. All patients with PBC do not respond to UDCA in the same
way. The transplant-free survival rate among UDCA-treated
patients remains signiﬁcantly lower than that of an age- and gen-
der-matched control population [17], indicating that there is a
need for new therapeutic options particularly for patients with
a suboptimal biochemical response to UDCA and predictive fac-
tors of a poor outcome [18]. Serum bilirubin was shown to be
the most potent prognostic marker in PBC as were also serum
albumin, prothrombin time and cirrhosis, the traditional prog-
nostic factors in advanced liver disease. More recently, the bio-
chemical response to UDCA has been shown to predict long-
term outcomes and, thus, may be applied as a simple selection
criterion for clinical trials [18–23].
In PSC, UDCA may lower disease progression but long-term
efﬁcacy remains uncertain [24,25]. A placebo-controlled trial
using very high doses of UDCA (28–30 mg/kg/day) showed that
UDCA was not only ineffective but also harmful in that more
patients developed varices or were listed for liver transplantation
[26]. Therefore, no evidence-based recommendation can be given
for normal doses, but very high-dose regimens should be avoided
[16,27].S26 Journal of Hepatology 201UDCA therapy has been used for a number of other clinical
conditions. Efﬁcacy is regarded as likely in ABCB4 deﬁciency with
progressive familial intrahepatic cholestasis type 3 (PFIC-3) and/
or low phospholipid-associated cholelithiasis (LPAC syndrome)
and cystic ﬁbrosis-associated liver disease (CFALD). Efﬁcacy is
regarded as uncertain in various forms of sclerosing cholangitis,
drug-induced liver injury, progressive familial intrahepatic
cholestasis type 1 & 2, sarcoidosis hepatis, prevention of bile duct
injury after liver transplantation, and total parenteral nutrition
(TPN)-induced cholestasis [16]. In all of these conditions (as in
PSC), no clear-cut survival beneﬁt with UDCA has been shown.UDCA: major molecular mechanisms and sites of action
Dried black bear’s bile was recommended more than a thousand
years ago for treatment of jaundice at times of the Tang dynasty
in China as mentioned above. UDCA may form up to 60% of black
bear’s total BAs [28] whereas it forms only 1–3% of total BAs in
human bile, but is enriched to 40% in bile of patients with PBC
and healthy volunteers treated with therapeutic UDCA doses
(13–15 mg/kg/day) [29]. UDCA has potent anticholestatic and
antiapoptotic properties in conditions of hepatocellular (e.g.,
intrahepatic cholestasis of pregnancy (ICP)) or cholangiocellular
cholestasis (e.g., early PBC).
Early after the ﬁrst peer-reviewed reports on UDCA in PBC
[7,8] it was proposed that UDCA exerts its hepatoprotective
effects in cholestatic liver disease mainly by stimulating impaired
hepatobiliary secretion [30]. In the 1990’s, UDCA was then unrav-
eled as a potent intracellular signaling molecule acting as a Ca2+
agonist [31–34] and an activator of protein kinase C (cPKCa) [35–
37], mitogen-activated protein kinases (MAPK: Erk1/2, p38MAPK)
[38,39] and a5b1 integrins [40,41] in hepatocytes. It was earlier
proposed [33,42] and later experimentally proven that UDCA
conjugates as potent signaling molecules that might stimulate
secretion of hepatocytes (and cholangiocytes [43]) by activating
vesicular exocytosis and carrier insertion into their apical mem-
branes resulting in choleretic effects via a dual MAPK- and inte-
grin-dependent mechanism in healthy liver [39,40] and in
anticholestatic effects via Ca2+-/type II inositol-1,3,4-triphos-
phate receptor/cPKCa/PKA-dependent mechanisms in cholestatic
liver [44–46]. It remains to be proven if these complex post-tran-
scriptional molecular mechanisms unraveled in experimental
animals may explain the choleretic and anticholestatic effects
of UDCA in man.
More recently, the ‘biliary HCO3 umbrella’ hypothesis has
been introduced as a protective mechanism for hepatocytes and
cholangiocytes against the toxic effects of millimolar BA mono-
mers present in bile [47]. This hypothesis indicates that biliary
HCO3 secretion in humans serves to maintain an alkaline pH near
the apical surface of hepatocytes and cholangiocytes to prevent
the uncontrolled membrane permeation of protonated glycine-
conjugated BAs which have a pKa P4. Notably, the experimental
proof of concept also unraveled that an intact ‘biliary HCO3
umbrella’ is critically dependent on adequate function of the
major HCO3 exporter, the Cl/HCO3 exchanger AE2, and an intact
biliary glycocalyx in human cholangiocytes [48]. Functional
impairment of this biliary HCO3 umbrella or its regulation would
lead to enhanced vulnerability of cholangiocytes and periportal
hepatocytes towards the attack of apolar hydrophobic BAs.
Notably, UDCA stimulates biliary HCO3 secretion under5 vol. 62 j S25–S37
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Fig. 1. Major mechanisms and sites of action of UDCA in cholestatic diseases.
(A) UDCA conjugates exert anticholestatic effects and stimulate bile acid (BA) and
organic anion secretion by mainly post-transcriptional molecular mechanisms at
the level of the hepatocytes (for details see text). UDCA also stimulates biliary
HCO3 secretion at the level of hepatocytes and cholangiocytes leading to
stabilization of a ‘biliary HCO3 umbrella’ [47,48]. Antiapoptotic and anti-
inﬂammatory effects are discussed in the text. (Figure modiﬁed from [28],
courtesy of G. Paumgartner). (b) A closer look into the ‘biliary HCO3 umbrella’ on
the apical membrane of a cholangiocyte [47,48]. The 20–40 nm glycocalyx on the
apical membrane may trap HCO3 molecules in order to create an alkaline milieu
which keeps bile acids in a negatively loaded state (bile salts) and, thereby,
prevents carrier-independent invasion of apolar hydrophobic BA into cholangio-
cytes (and hepatocytes) [47,48]. (Figure modiﬁed after Maillette de Buy Wenniger
et al. Dig Dis 2015, in press).
JOURNAL OF HEPATOLOGYexperimental conditions as well as in patients with PBC [28,49]. A
defective AE2 expression [50,51] and biliary HCO3 secretion [49]
have been described in patients with PBC. Thus, stabilization of
the ‘biliary HCO3 umbrella’ may be a crucial mechanism of action
of UDCA in cholestatic liver diseases (Fig. 1).Journal of Hepatology 201The original proposal that UDCA may exert anticholestatic
effects by removing major hydrophobic BAs such as CDCA or
DCA from the circulating BA pool was disproved during short-
term UDCA treatment when cholestasis improved, but hydropho-
bic BA pool sizes remained stable [52]. In contrast to hydrophobic
BAs such as CDCA or lithocholic acid (LCA), UDCA also does not
markedly affect transport protein expression in vivo at the tran-
scriptional level to modulate transport capacity and probably
exerts only limited post-transcriptional modiﬁcation of carrier
expression [53].
Antiapoptotic mechanisms [28,54–56] and effects on endo-
plasmic reticulum stress may contribute to the cytoprotective
action of UDCA in cholestatic liver disease as summarized else-
where [28]. Of note, UDCA has early been described to act as a
glucocorticoid receptor (GR) agonist in a ligand-independent
way [57–60]. Interaction of UDCA with the GR has been linked
to the antiapoptotic effect of UDCA in TGF-b1-induced liver-
cell apoptosis [61]. Thus, antiapoptotic and anti-inﬂammatory
actions of UDCA in the liver and bile ducts may at least in part
be secondary to this and the numerous effects described
above.Norursodeoxycholic acid: experimental and clinical effects
24-norursodeoxycholic acid (norUDCA) is a side chain shortened
UDCA derivate which lacks a methylene group resulting in a rela-
tive resistance to amidation with taurine or glycine compared
with UDCA [62–65]. As a result, norUDCA is passively absorbed
from cholangiocytes and undergoes ‘cholehepatic shunting’
(instead of a full enterohepatic cycle) which generates a HCO3
anion resulting in induction of a HCO3-rich hypercholeresis
[62,65,66] counteracting intrinsic BA toxicity [67] and reinforcing
the ‘biliary HCO3 umbrella’ [47,48]. Cholehepatic shunting may
also allow ‘ductular targeting’ of drugs [62,68]. As a proof of prin-
ciple, taurine-conjugated norUDCA and bis-norUDCA (resulting
from additional side chain shortening) lack cholehepatic shunting
properties [69], emphasizing the unique properties of norUDCA.
In addition, norUDCA is more hydrophilic and thereby less toxic
for hepatocytes and cholangiocytes in vitro than its mother com-
pound UDCA [70] which may further help to counteract (intrin-
sic) biliary toxicity. Notably, neither norUDCA nor UDCA have
relevant afﬁnities for dedicated BA receptors such as the farne-
soid X receptor (FXR) or G protein-coupled plasma membrane
receptor TGR5 [71]. norUDCA (but not ‘‘conventional’’ UDCA or
bis-norUDCA) reversed sclerosing cholangitis in the experimental
Mdr2/Abcb4 knockout mouse (Mdr2/Abcb4/) cholangiopathy
model for sclerosing cholangitis, while the mother compound
UDCA even aggravated bile infarcts in cholestatic conditions with
biliary obstruction [68–70]. Moreover, norUDCA has anti-lipo-
toxic, anti-proliferative, anti-ﬁbrotic as well as anti-inﬂammatory
effects which may complement stimulation of HCO3 secretion
with BA detoxiﬁcation and induction of alternative export via
overﬂow systems at the basolateral membrane [68,71] (Fig. 2).
Notably, in a hepatocellular model of cholestasis induced by
TLCA, taurine-conjugated norUDCA had anti-cholestatic and anti-
apoptotic properties, suggesting that combination of UDCA and
norUDCA may be superior to UDCA or norUDCA monotherapy
in biliary disorders in which both hepatocyte as well as cholan-
giocyte dysfunction are involved in the pathophysiology of the
disease [72].5 vol. 62 j S25–S37 S27
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Fig. 2. Proposed mechanisms of action of norUDCA in the Mdr2 (Abcb4)/ model of sclerosing cholangitis. As hydrophilic bile acid (BA) and by generating a
bicarbonate-rich (hyper)choleresis due to cholehepatic shunting, norUDCA counteracts intrinsic biliary toxicity resulting from absent phospholipid (PL) secretion with
increased free non-micellar bound BAs in this model. Importantly, cholehepatic shunting allows ‘ductal targeting’ of anti-inﬂammatory, anti-ﬁbrotic and anti-proliferative
effects to injured bile ducts, resulting in ‘ductal healing’. norUDCA also counteracts lipotoxic fatty acid composition and promotes BA detoxiﬁcation and elimination via
basolateral efﬂux pumps facilitating their subsequent renal excretion. Modiﬁed after [200].
Table 1. Potential future therapeutic agents which modulate bile formation
and secretion. See text for potential molecular mechanisms of action and clinical
observations.
Pharmacologic 
agents under study 
(examples)
Targets Natural ligands
(examples)
Nuclear receptors
Obeticholic acid 
PX-102
FXR Chenodeoxycholic acid
Cholic acid
All-trans retinoic acid RXR Retinoic acid (Vit. A)
Bezafibrate
Fenofibrate
Ciprofibrate
PPARα Free fatty acids
Budesonide and
other corticosteroids
GR
PXR
Cortisol
Rifampicin
Statins
Corticosteroids
PXR Lithocholic acid
ReviewnorUDCA is currently undergoing further clinical development
in humans. The ﬁnal results of a double-blind, randomized,
European multicenter, placebo-controlled, comparative,
exploratory phase II dose-ﬁnding trial in the treatment of PSC
are expected for 2015 [73]. Future clinical indications, next to
PSC, may include PBC and cystic ﬁbrosis-associated liver dis-
ease/cholangiopathy where defects of the biliary HCO3 umbrella
may also be involved [47,48]. Notably, norUDCA induces a HCO3-
rich choleresis independent of cystic ﬁbrosis transmembrane
conductance regulator (CFTR) [69] consistent with the concept
of cholehepatic shunting which does not appear to involve active
transport processes [62]. Promotion of HCO3-rich bile ﬂow may
also beneﬁcially affect sclerosing cholangitis of critically ill
patients, non-anastomotic strictures following liver transplanta-
tion, or ABCB4 deﬁciency with progressive familial intrahepatic
cholestasis type 3 (PFIC-3) [47,74]. Collectively, these broad and
multiple levels of mechanisms make norUDCA an attractive
therapeutic agent for cholangiopathies [73].Vitamin D VDR 1.25-diOH-vitamin D
Membrane receptors
FGF19
NGM 282
FGFR4 FGF19
Int-777 TGR5 Chenodeoxycholic acid
Lithocholic acid
ASBT inhibitors ASBT Conjugated bile acids
Bile acid derivatives
norUDCA ?FXR – FGF19: experimental and clinical effects
The discovery of the nuclear hormone receptors in the 1990s was
followed by the notion that BAs serve as their ligands [75–79].
This caused a dramatic turn around in BA research. In addition
to understanding the role of BAs in regulating their own synthesis
and transport, it is now clear that the post-prandial surge of BAs
through intestine and liver, and to a lesser degree through adi-
pose tissues, kidney and muscle, triggers signals that prepare
the organism for production or storage of energy [80]. Recent
studies also show that BA signaling is a major regulator of the cir-
cadian rhythm of metabolism [81,82].
Nuclear hormone receptors act as intracellular ligand-activat-
ed receptors (Table 1). Cholic acid (CA) and CDCA bind to the FXRS28 Journal of Hepatology 201(NR1H4). FXR, as a heterodimer with the all-trans retinoic acid
(ATRA) receptor RXR, binds to the LR-1 DNA motive in the pro-
moter region of target genes [75,83]. FXR target genes include5 vol. 62 j S25–S37
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Fig. 3. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are absorbed in the
ileum via the apical sodium-dependent bile acid transporter (ASBT) (1). About
5% of bile acids (BA) spill over into the colon where they are converted to the
secondary BAs deoxycholate and lithocholate by 7a-hydroxylase-containing
bacteria (2). In the mucosa cells of the ileum, BAs bind to FXR (3). Ligand-bound
FXR activates the transcription of FGF19 and subsequently FGF19 is secreted into
the portal circulation. At the hepatocyte surface, FGF19 binds to FGFR4/bKlotho
(4). In the ileum, BAs exit the mucosa cells via the organic solute transporter
OSTab (5). BAs are taken up in the liver via the Na+-taurocholate-cotransporting
polypeptide (NTCP) (6). In hepatocytes, BAs bind to FXR and this activates
transcription of short heterodimer partner SHP. FGF19 via FGFR4/bKlotho–SHP
and BA-activated FXR-SHP block HNF4a and LRH-1 - mediated transcription of
CYP7A1. CYP7A1 is the rate-limiting enzyme in the conversion of cholesterol to
7a-hydroxycholesterol, 7a-hydroxy-4-cholesten-3-one, CA and CDCA. Bile salts
exit the liver via BSEP, the canalicular bile salt export pump (7). Deoxycholic acid
(DCA) and lithocholic acid (LCA) are secondary bile salts that enter and exit the
colon mucosa passively via the help of transport proteins (8). At the colon mucosa
surface DCA and LCA bind to TGR5 (9). This stimulates the production of cyclic
AMP (cAMP) which triggers production and secretion of glucagon-like peptide 1
(GLP-1) (10). DCA and LCA are high afﬁnity ligands for TGR5 in a variety of tissues.
In these tissues TGR5 has metabolic and anti-inﬂammatory effects (e.g., in
adipose tissue TGR5 stimulates the expression of DIO2 that mediates the
conversion of T4 to T3; in Kupffer cells TGR5 inhibits the secretion of cytokines).
JOURNAL OF HEPATOLOGYshort heterodimer partner (SHP) and ﬁbroblast growth factor
(FGF)19 (Fgf15 in rodents) and the transporters BSEP, OST a/b,
and putatively MRP3 and MRP4 [84–88]. SHP is a protein that
in the liver suppresses the HNF4a and LRH-1 mediated transcrip-
tion of CYP7A1, the rate-determining enzyme in BA synthesis.
SHP also plays a complex role in glucose, lipid and energy meta-
bolism [89–91]. Therefore SHP is a crucial effector molecule in
the regulation of metabolism inside and outside the liver (Fig. 3).
FGF19 and FGF21 are members of the ﬁbroblast growth factor
family [92]. These proteins serve as hormones in inter-organ
signaling (FGF19, gut to liver; FGF21, liver to adipose tissues)
supporting the actions of FXR and peroxisome proliferator-
activated receptor alpha (PPARa) [93–95]. If after a meal the gall-
bladder contracts, BAs enter the intestine, are re-absorbed in the
ileum where they activate FXR before they enter the portal circu-
lation and are taken up in the liver. In the ileum, FXR activation
leads to FGF19 expression. FGF19 enters the portal circulationJournal of Hepatology 201and binds to the FGFR4/bKlotho receptor on hepatocytes (Fig. 3).
This activates a series of MAP-kinases (e.g. ERK-1 and ERK-2)
and suppresses CYP7A1 expression [88]. Like FXR, FGF19 has
strong metabolic effects as it suppresses the insulin-stimulated
expression of the lipogenic enzymes FAS and SREBP1c and stimu-
lates glycogen synthesis and reduces the expression of gluco-
neogenic enzymes [96–98]. Thus, FGF19 has insulin-like effects
except that it inhibits lipogenesis while insulin stimulates it.
There is a debate on the importance of direct BA/FXR/SHP signal-
ing in the liver vs. indirect signaling by FGF19 from gut to liver in
the repression of CYP7A1 [99,100]. Both actions probably rein-
force each other. SHP and additional factors (Shp2 in mice
[101]) are required for FGF19/FGFR4 signaling in the liver.
During fasting FGF21 is produced in the liver as a result of free
fatty acid-stimulated PPARa [102]. FGF21 increases fatty acid
oxidation and ketogenesis in the liver and in cooperation with
PPARc improves insulin sensitivity and glucose uptake in white
adipose tissue [103–105]. Notably, FGF21 stimulates adiponectin
secretion in white adipose tissue of mice [106,107].
BAs in excess are cytotoxic and their synthesis is tightly
regulated. In liver disease this regulation may be insufﬁcient or
may have gone astray and this prompted researchers to design
BA analogues and non-BA compounds with high FXR afﬁnity
[108–112]. These agents are tested as drugs for the treatment
of PBC, PSC and non-alcoholic fatty liver disease (NAFLD). This
latter indication rests on the fact that FXR inhibits lipogenesis
and gluconeogenesis and improves insulin sensitivity, important
factors in the pathogenesis of NAFLD/NASH.
FXR agonists such as the BA derivative obeticholic acid (OCA,
6-ethyl-chenodeoxycholic acid) [113] and the non-BA PX-102 are
tested in phase II and phase III trials [114]. In a recent study, PBC
patients with an incomplete response to UDCA, received 10 mg,
25 mg, and 50 mg OCA or placebo [113]. UDCA therapy was con-
tinued. The results showed a 20% decrease in alkaline phos-
phatase in 70% of patients. Gamma-glutamyltransferase, CRP
and IgM also decreased. However, ﬁfty percent of PBC patients
in this study suffered from pruritus at baseline and this did not
improve. Pruritus even worsened in patients receiving 25 or
50 mg OCA. In a new phase III trial, pruritus is addressed by using
a lower dose (610 mg) of OCA (NCT01473524). Pruritus as a side
effect of OCA was also observed in a NASH trial suggesting that
pruritus may be directly OCA- and not disease-related. The
mechanism of OCA-related pruritus remains unclear [115].
As potential drugs, FGF19 and FGF21 have the disadvantage
that they need to be injected but this may be counterbalanced
by different action proﬁles. The non-tumorigenic FGF19 deriva-
tive NGM 282 in combination with UDCA has entered phase II
in PBC patients [116] (NCT02135536).
For PSC therapeutic possibilities are limited. FXR agonists can
be considered but FGF19 induction by these agonists may be a
caveat. FGF19 has carcinogenic properties and effects on cholan-
giocarcinogenesis have to be carefully considered [117].
Nevertheless, ATRA, a ligand of RXR, the heterodimer of FXR, in
combination with UDCA, in a short-term small non-randomized
trial, has most recently been reported to reduce alkaline phos-
phatase, serum ALT and BA levels (Assis et al., unpublished).TGR5: experimental effects
In addition to FXR and other nuclear hormone receptors, BAs can
also signal through a membrane-bound BA-speciﬁc receptor5 vol. 62 j S25–S37 S29
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TGR5 (also known as GPBAR1 or M-BAR/BG37) [118]. The most
potent endogenous TGR5 activator is LCA followed by DCA
[119], while other BAs are less potent. Of note, TGR5 is expressed
in various tissues with low or even absent FXR such as spleen,
lung or adipose tissue [118,120] with the highest expression in
gallbladder and colon [121–123]. In liver, sinusoidal endothelial
cells, Kupffer cells and intrahepatic bile ducts express TGR5 (with
high expression in human and rat, lower in mouse), while
hepatocytes and quiescent stellate cells do not express TGR5
[124–126].
TGR5 activation inhibits pro-inﬂammatory cytokine produc-
tion, migration and phagocytic activity of macrophages and
Kupffer cells [120,124], in part by suppression of NF-jB signaling
[127] [120,128,129]. Accordingly, mice lacking TGR5 display
aggravated liver injury after LPS challenge [129]. TGR5 is also
involved in modulation of intestinal inﬂammation, motility, and
improves intestinal barrier function thereby protecting from
DSS induced colitis in rodents [130–134]. These ﬁndings may
be of potential relevance for the gut-liver axis in cholangiopathies
such as PSC.
Mice lacking TGR5 have a decreased total BA pool size [121],
increased CYP7A1 gene expression [123] and a more hydrophobic
BA composition [135] which may be due to the impact of BA-me-
diated TGR5 activation in inhibiting gallbladder contractility. As
such, TGR5 activation by hydrophobic BAs inhibits gallbladder
smooth muscle contractility [136]. TGR5/ mice display pro-
longed cholestasis, exacerbated inﬂammatory response and more
severe liver injury after partial hepatectomy, dietary BA-chal-
lenge or bile duct ligation [135,137]. Importantly, TGR5 polymor-
phisms in PSC patients may imply a potential role in
cholangiocyte pathophysiology [138,139]. Cholangiocytes
express TGR5 at the apical membrane/cilia where it may sense
the luminal BA concentration and regulate cholangiocellular
HCO3/ﬂuid secretion via CFTR and AE2 [122]. Surprisingly, a
highly potent TGR5 agonist (INT-777) failed to induce HCO3 out-
put and bile ﬂow in healthy mice as well as in Mdr2/ model
without improvement of bile duct injury [140], ﬁndings which
could be explained by relatively low TGR5 expression in mouse
cholangiocytes. However, mice overexpressing TGR5 showed less
liver injury in a mouse model of xenobiotic (DDC)-induced scle-
rosing cholangitis, while mice lacking TGR5 showed aggravation
of inﬂammation and ﬁbrosis [141]. Collectively, these ﬁndings
suggest a critical role of TGR5 for liver protection against BA over-
load, primarily through the control of bile hydrophobicity and
cytokine secretion. Conversely, TGR5 deﬁcient mice are protected
against lithogenic diet-induced gallstone formation [123] sug-
gesting that inhibition rather than activation of TGR5 may be
beneﬁcial for gallstone disease. On the other hand, TGR5 activa-
tion of biliary HCO3 secretion could theoretically counteract
gallstone formation, at least at the level of bile ducts.
Importantly, activation of TGR5 may also have some unde-
sired off-target effects. For example, bile reﬂux-induced pancre-
atitis has been linked to BA-mediated TGR5 activation in mouse
pancreas [142]. Moreover, TGR5 activation promoted oxidative
stress in astrocytes [143] and activated AKT signaling in car-
diomyocytes possibly contributing to cardiac hypertrophy under
cholestatic conditions [144]. More recently, TGR5 has also been
implied in the pathogenesis of pruritus [145,146]. TGR5-activa-
tion by BAs was linked to increased hepatocellular apoptosis
[147] through activation of c-Jun N-terminal kinase (JNK) signal-
ing pathways while cholangiocytes seem to evade apoptosis viaS30 Journal of Hepatology 201TGR5 [148]. Importantly, TGR5 is also highly expressed in gastric
and oesophageal adenocarcinoma as well as gallbladder carcino-
ma where it promotes cell proliferation in response to BA [149]
Such extrahepatic ‘‘off-target effects’’ may need consideration
when developing BA receptor ligands as therapeutics in patients
with liver disease.PPARa: experimental and clinical effects
The PPARs are enriched in tissues with high energy metabolism
such as liver (PPARa, NR1C1), skeletal muscle, heart and gastroin-
testinal tract (PPARb/d, NR1C2) and adipose tissue (PPARc,
NR1C3) [150]. Fatty acids and their derivatives are the natural
ligands for these receptors. By stimulating fatty acid oxidation,
PPARa has anti-steatotic effects. However, PPARa also has anti-
inﬂammatory actions. It was recently argued that the anti-in-
ﬂammatory action of PPARa is based on trans-repression of AP1
and NF-jB signaling while its metabolic action depends on direct
trans-activation of metabolically active target genes. By introduc-
ing a mutation in the zinc-ﬁnger domain of PPARa, a DNA-bind-
ing deﬁcient PPAR derivative with maintained anti-inﬂammatory
activity but no metabolic activity was recently produced [151].
For the application of PPAR agonists in cholestatic liver dis-
ease the notion that the canalicular phospholipid translocator
MDR3 is a PPARa responsive gene is relevant [152,153].
Treatment with PPAR agonists (ﬁbrates) increases MDR3 inser-
tion into the canalicular membrane [153–155]. This stimulates
phosphatidylcholine secretion and protects cholangiocytes again-
st bile salt toxicity. This is among the rationales to test ﬁbrates in
PBC and PSC. Other actions of PPAR agonists, that underscore
their possible therapeutic use, are repression of CYP7A1 and
induction of CYP3A4 enzymes that are instrumental for bile salt
synthesis and detoxiﬁcation, respectively [156]. In cholestasis
inﬂammatory and pro-ﬁbrotic genes are activated and it is possi-
ble that the anti-inﬂammatory action of PPAR agonists is equally
important [157]. In most trials in which ﬁbrates were tested as
treatment of UDCA-refractory PBC, the endpoint has been a
decrease of alkaline phosphatase [158]. In a recent meta-analysis
on studies comparing patients treated with UDCA plus bezaﬁ-
brate vs. UDCA alone, combination therapy performed better than
monotherapy regarding biochemical parameters but as for symp-
toms and survival there was no difference (meta-analysis in
[159]). In the one study wherein liver stiffness was measured
no change was observed [160]. Notably, a signiﬁcant improve-
ment of pruritus in PBC patients receiving bezaﬁbrate was
recently reported [160]. Rigorous testing of histologic endpoints
and transplantation-free survival needs to be performed but
ﬁbrates may be too weak a PPAR agonists to be successful.
Currently stronger PPAR agonists are developed with consider-
able anti-inﬂammatory activity [150]. Although primarily devel-
oped for the treatment of NASH, these may be promising
agents for the treatment of PBC and PSC as well (Table 1).The pregnane X receptor (PXR): experimental and clinical
effects
The PXR (NR1I2) has a critical role in regulating the expression of
genes involved in detoxiﬁcation and metabolism of BA, drugs and
other toxins [161]. PXR modulates expression of CYP3A4 and5 vol. 62 j S25–S37
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CYP7A1 [162,163], SULT2A1 [164], UGT1A1, UGT1A3, and
UGT1A4 [165,166], MDR1 [167], MRP2 [168], MRP3 [169], and
OSTb [166]. Cholestatic PXR knockout mice exhibited more hep-
atic damage than wild-type mice both after bile duct ligation and
cholic acid feeding, [170–172]. The potent PXR ligand 5-pregnen-
3b-ol-20-one-16a-carbonitrile (PCN) reduced (litho-)cholic acid-
induced liver injury in wild-type mice, but not in PXR knockout
mice [163,172]. Marked upregulation of the basolateral BA efﬂux
transporter MRP3 (ABCC3) may have been crucial in mediating
the beneﬁcial effect of PCN [172].
Human PXR agonists include lithocholic acid and a number of
drugs including rifampicin, statins, corticosteroids, phenobarbi-
tal, and St. John’s wort. The antibiotic rifampicin is a potent
human PXR activator and an evidence-based treatment for pruri-
tus in cholestatic patients [16]. Rifampicin has been reported to
improve serum liver tests in PBC [173,174]. In otherwise healthy
gallstone patients, rifampicin induced upregulation of UGT1A1
and MRP2 facilitating bilirubin elimination and increased
CYP3A4 expression facilitating detoxiﬁcation of BAs [53].
Rifampicin also markedly induced CYP3A metabolism in patients
with early stage PBC and healthy controls [175]. All these effects
were not observed with UDCA indicating that the combined use
of UDCA and rifampicin might have synergistic beneﬁcial effects
in patients with non-obstructive cholestasis [175]. Rifampicin
was reported to be safe in cholestatic liver disease during short-
term use for up to two weeks [176]. However, severe hepatotox-
icity has been reported in up to 13% of patients with cholestatic
disorders after use for more than 4 weeks [174]. Strikingly, rifam-
picin has been shown most recently to completely reverse severe
persistent hepatocellular secretory failure [166] induced by drugs
(e.g., clavulanic acid, ﬂucloxacilline, estrogen + progesterone,
testosterone, total parenteral nutrition) or transient biliary
obstruction (e.g. choledocholithiasis, pancreatic carcinoma) in
formerly healthy individuals, an enormous relief for otherwise
desperate patients [166]. A prospective, controlled trial on the
promising effect of PXR agonists in severe persistent hepatocellu-
lar secretory failure is under preparation.The GR and UDCA: experimental and clinical effects
The use of glucocorticoids to suppress the inﬂammation in PBC
has been always considered as a very attractive approach, but
at the cost of serious side effects, especially aggravating osteope-
nia. Budesonide is a non-halogenated glucocorticoid mainly
absorbed in the small intestine. Of an oral dose, 90% is metabo-
lized during the ﬁrst liver pass in healthy individuals.
Compared with prednisolone, GR binding activity of budesonide
is 15–20 times higher, so its effect on liver inﬂammation may
be greater. In patients with inﬂammatory bowel disease and
autoimmune hepatitis, oral budesonide has been shown to exert
fewer systemic side effects than conventional corticosteroids
[177].
Recent studies have shed some light on the complex relation-
ships between GR activation and BAs. Glucocorticoids promote
hepatic cholestasis in mice by inhibiting the transcriptional
activity of the FXR [178] and increase intestinal apical sodium-
dependent bile salt transporter (ASBT) activity [179] while
promoting PXR-mediated hydroxylation and sulfation of
hydrophobic BAs [180]. Conversely, high BA concentrations
might promote SHP-mediated inhibition of GR activation [181]Journal of Hepatology 201that could explain some loss of anti-inﬂammatory effects of glu-
cocorticoids in cholestatic conditions. Taken together these data
suggest that classical glucocorticoids may have negative effects
in cholestatic conditions.
In contrast to other natural BAs, UDCA is a GR agonist [57–59].
Moreover, combination of budesonide and UDCA have been
shown to promote activity of the Cl/HCO3 exchanger AE2, the
key transporter involved in alkaline-rich choleresis in humans
[182].
Two randomized studies showed the GR (and PXR) agonist
budesonide (6–9 mg/day) combined with UDCA to be more effec-
tive in improving liver biochemistries and histology than did
UDCA alone in patients with stages I-III PBC [183,184]. This was
not observed in a study including late stage PBC patients who
also developed serious side effects [185]. In an open trial involv-
ing non-cirrhotic PBC patients with severe inﬂammation and bio-
chemical cholestasis not responding to UDCA, the combination of
UDCA, budesonide and mycophenolate mofetil – as a corticos-
teroid-sparing agent – achieved biochemical remission and
marked improvement of liver histology [186]. Combination ther-
apy (UDCA + budesonide) is currently being evaluated in compar-
ison to UDCA monotherapy in PBC patients with suboptimal
response to UDCA alone in a European multicenter randomized,
placebo-controlled trial. Because of its high ﬁrst-pass hepatic
clearance, budesonide should not be given to patients with evi-
dence of cirrhosis and portal hypertension as portosystemic
shunting may occur and development of portal vein thrombosis
has been described [187].The vitamin D receptor (VDR): experimental ﬁndings
VDR ligands represent potentially attractive agents for pharma-
cotherapy of autoimmune cholestatic disorders because they
may inﬂuence several key processes involved in the pathogenesis
such as innate and immune activation, BA metabolism and
detoxiﬁcation, bile duct integrity and ﬁbrogenesis. VDR is
expressed in almost all immune cells and mediates the
immunoregulatory properties of vitamin D. Indeed, vitamin D
through VDR interferes directly with T cells by inhibiting the pro-
duction of T-helper-1 (TH1) type cytokines, while promoting
those of the TH2 subtype. Furthermore, vitamin D inhibits den-
dritic cell differentiation resulting also in a decrease in TH1 cell
development. Taken together, these observations indicate that
vitamin D through VDR diminishes the effector T cell response
suggesting that the vitamin D-VDR axis may be involved in
autoimmune diseases [188]. In bile duct epithelial cells, activa-
tion of VDR by BAs or vitamin D induces expression of cathelicid-
in, an anti-microbial peptide known to be protective against
bacterial infection. Cathelicidin is known to neutralize the delete-
rious effects of LPS that accumulates in the biliary tree in ﬁbros-
ing cholangiopathies [189].
Treatment with VDR agonists stimulates BA detoxiﬁcation
enzymes (such as CYP3A4 and SULT2A1) in the liver and intes-
tine, and protects against lithocholic acid hepatotoxicity [190].
1,25(OH)2D3 was also shown to decrease hepatic Cyp7a1
expression by increasing the expression of Fgf15 in the intes-
tine. Consistently, Cyp7a1 expression was increased in mice
lacking VDR when compared to wild-type mice, indicating that
intestinal VDR activity controls the basal expression of Cyp7a1
[191].5 vol. 62 j S25–S37 S31
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The anti-ﬁbrotic potential of VDR stimulation has been
demonstrated in several models of liver ﬁbrosis, among them
the Mdr2 (Abcb4)/ mice [192,193]. Recently, the vitamin
D-VDR axis has been shown to modulate ﬁbrogenesis and
hepatic stellate cell activity through a complex mechanism
involving epigenetic modiﬁcations induced by the SMAD
pathway [194].ASBT inhibitors
The ASBT (SLC10A2) at the luminal surface of ileum enterocytes
transports conjugated BA from the gut lumen into the entero-
cytes [195]. From here BA are secreted into the portal circulation.
Under normal physiological conditions ASBT works at maximum
capacity since overproduction of BA in the liver leads to increased
spill over of BA into the colon [196]. In the colon, BA activate
chloride channels and this causes watery diarrhea [197].
Moderate inhibition of ASBT however can have beneﬁcial effects
while avoiding diarrhea. ASBT inhibition lowers the intra-mucos-
al concentration of BA with less activation of FXR, lowered syn-
thesis of FGF19 and unrepressed expression of CYP7A1 in the
liver. This causes an enhanced conversion of cholesterol to BA
and lowers serum cholesterol. Spill over of BA into the colon will
stimulate 7a-dehydroxylation of BA and stimulate TGR5. This
enhances GLP-1 secretion which will increase insulin secretion
by the pancreas and improve insulin sensitivity. Anionic
exchange resins such as colesevalam have a similar effect
[198,199]. Thus, ASBT inhibitors are potential drugs for treatment
of NAFLD. ASBT inhibitors interrupt the enterohepatic circulation
of BA and this may reduce the circulating BA pool, given that the
loss exceeds the upregulated BA synthesis. This may be beneﬁcial
in cholestatic liver disease but convincing clinical data are cur-
rently lacking.Conclusion
Three decades after the introduction of UDCA as the ﬁrst
anticholestatic agent into clinical practice to treat patients with
chronic cholestatic disorders, an enormous progress in the under-
standing of the molecular pathophysiology of hepatocellular and
cholangiocellular cholestasis has led to the development of a
variety of novel therapeutic options which are currently under
evaluation. Novel immunomodulating approaches are beyond
the scope of this review. While UDCA exerts its anticholestatic
effects mainly by post-transcriptional mechanisms as a potent
intracellular signaling agent and secretagogue, candidates for
future combined treatment with UDCA mostly represent tran-
scriptional modulators of secretion and cell protection or mem-
brane receptor agonists. Among these, evaluation of agonists for
FXR, GR, and PPARa in combination with UDCA is far advanced
to large scale phase III trials in chronic cholestatic disorders such
as PBC. The next line of upcoming therapeutic agents, often in
combination with UDCA, for cholestatic disorders includes the
23C-analogue of UDCA, norUDCA, as well as PXR agonists,
FGF19 derivatives and ASBT inhibitors. While there was 30 years
ago no effective treatment available, promising times for patients
with cholestatic disorders and their caring physicians are visible
on the horizon.S32 Journal of Hepatology 201Financial support
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